AGENUS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.46 USD | -3.38% |
|
-6.87% | -6.63% |
Financials (USD)
| Sales 2024 * | 206M | Sales 2025 * | 183M | Capitalization | 325M |
|---|---|---|---|---|---|
| Net income 2024 * | -185M | Net income 2025 * | -230M | EV / Sales 2024 * | 1.57 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.77 x |
| P/E ratio 2024 * |
-1.73
x | P/E ratio 2025 * |
-1.78
x | Employees | 389 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.77% |
More Fundamentals
* Assessed data
More news
Latest transcript on Agenus Inc.
More recommendations
More press releases
| 1 day | -3.38% | ||
| 1 week | -6.87% | ||
| Current month | -1.47% | ||
| 1 month | +44.49% | ||
| 3 months | +28.90% | ||
| 6 months | +1.55% | ||
| Current year | -6.63% |
1 week
15.23
17.65
1 month
10.0519.69
Current year
4.7819.69
1 year
4.7838.60
3 years
4.78135.80
5 years
4.78135.80
10 years
4.78203.20
| Managers | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director of Finance/CFO | 58 | 95-12-31 | |
Craig Winter
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director/Board Member | 66 | 16-05-16 | |
Susan Hirsch
BRD | Director/Board Member | 71 | 20-10-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.15% | 26 M€ | -6.71% | - | |
| 0.01% | 775 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 15.46 | -3.37% | 423,008 |
| 24-06-13 | 16 | -5.44% | 520,787 |
| 24-06-12 | 16.92 | +0.83% | 335,230 |
| 24-06-11 | 16.78 | -2.27% | 397,870 |
| 24-06-10 | 17.17 | +3.43% | 495,925 |
Delayed Quote Nasdaq, June 14, 2024 at 04:00 pm EDT
More quotes
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.46
USD
Average target price
44.25
USD
Spread / Average Target
+186.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.63% | 325M | |
| +40.80% | 53.67B | |
| +35.79% | 38.86B | |
| -8.05% | 38.76B | |
| -8.98% | 27.27B | |
| +10.69% | 25.91B | |
| -16.21% | 20.29B | |
| +31.00% | 12.78B | |
| +28.51% | 12.18B | |
| -1.67% | 11.96B |
- Stock Market
- Equities
- AGEN Stock
